GlassScriptPhysician profile
Rinna Conol Johnson
NPI 1104834456
$10,550.40
in general payments reported to CMS, 2019-2025
35 companies · $2,040 in 2025
The $2,040 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,375 · 2020: $422 · 2021: $187 · 2022: $853 · 2023: $2,312 · 2024: $2,361 · 2025: $2,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,403 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,403.44 |
| Education | $310.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,788.15 | 2019-2025 | |
| Janssen Biotech, INC. | $1,079.02 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $829.51 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $727.87 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $496.64 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $490.49 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $479.18 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $457.47 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $408.28 | 2019-2025 | |
| Genzyme Corporation | $404.52 | 2019-2025 | |
| Incyte Corporation | $399.03 | 2021-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $385.29 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $373.48 | 2019-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $358.32 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $274.31 | 2019-2025 | Aklief, Oracea, Twyneo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $233.15 | 2019-2025 | Blu-U, Odomzo, Winlevi |
| Dermavant Sciences, INC. | $221.68 | 2022-2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $174.05 | 2019 | |
| Biofrontera INC. | $173.46 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.47 | 2023-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $121.11 | 2019 | |
| Mayne Pharma Commercial LLC | $85.32 | 2019-2023 | |
| Celgene Corporation | $76.06 | 2019 | |
| Revance Therapeutics, INC. | $69.01 | 2024-2025 | Daxxify |
| Kyowa Kirin, INC. | $54.84 | 2024 | Poteligeo |
| Merz North America, INC. | $51.03 | 2019-2024 | |
| Aclaris Therapeutics, INC. | $40.65 | 2019 | |
| Krystal Biotech INC | $26.06 | 2024 | Vyjuvek |
| Integra Lifesciences Corporation | $24.42 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Fresenius Kabi USA, LLC | $22.45 | 2023 | Idacio |
| Sandoz INC. | $22.44 | 2023 | Hyrimoz |
| Botanix Sb INC | $21.64 | 2025 | Sofdra |
| Almirall LLC | $17.88 | 2019 | |
| Sientra, INC. | $12.88 | 2020 | |
| Prugen, INC. Pharmaceuticals | $8.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rinna Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.